EntityRisk - Crunchbase Company Profile & Funding

Overview

EntityRisk

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About EntityRisk

CB Rank

294984

EntityRisk develops software for financial innovation in healthcare, focusing on drug pricing and access uncertainty.

Founded

obfuscation

Private

Princeton, New Jersey, United States

11-50

entityrisk.com

Analytics

Financial Services

Market Research

Key People

Neal Masia: Co-Founder and CEO
Dana Goldman: Founder

Details

Legal Name

EntityRisk, Inc.

Operating Status

Active

Company Type

For Profit

Founders

Dana Goldman, Darius Lakdawalla, Neal Masia

About the Company

EntityRisk specializes in developing software solutions aimed at transforming financial innovation within the healthcare sector. The company focuses on addressing the complexities of drug pricing and access by managing the full spectrum of uncertainty. Through its software, EntityRisk enables healthcare innovators and payers to effectively measure

and manage risks associated with healthcare economics. Founded by Dana Goldman, Darius Lakdawalla, and Neal Masia, who are recognized health economists, EntityRisk combines expertise and technology to support biopharmaceutical companies and investors. The company recently introduced the PROVEN™ software platform, designed to assist biopharma innovators and investors in navigating the uncertainties of drug development and market access.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

PROVEN™ Platform

A software platform that predicts and quantifies the real-world value and risks of new medical technologies using clinical, financial, and real-world data.

ValueML™

A tool that simulates distributions of value-based prices and cost-effectiveness outcomes across various value assessment frameworks.